Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

CELLMID LIMITED

INVESTOR PRESENTATION - CELLMID LIMITED

ASX:CDY

CELLMID LIMITED

Health Care

Cellmid Limited (CDY) is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets in novative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. They operate through two business segment Midikine and Consumer health.

Read more

Market Cap

12.52m

Price at Close

$0.1

4w avg. Volume

220.35k

4w avg. Turnover

$24.51k

Announcements
announcementt+2 movementdate
  • Letter to Shareholders - Notice of Annual General Meeting

    Notice Of Meeting

  • -

    30 Oct 2020

-

30 Oct 2020
  • Notice of Annual General Meeting/Proxy Form

    Notice Of Meeting

  • -

    30 Oct 2020

-

30 Oct 2020
  • Appendix 4C and Quarterly Activity Report

    Commitments test entity quarterly reports · Market sensitive

  • -8.70%

    21 Oct 2020

-8.70%

21 Oct 2020
  • Board Renewal To Align With Consumer Health Growth Strategy

    Company Administration

  • +10.00%

    20 Oct 2020

+10.00%

20 Oct 2020
  • Date of Annual General Meeting

    Notice Of Meeting

  • -8.00%

    12 Oct 2020

-8.00%

12 Oct 2020
  • Section 249D Notice

    Notice Of Meeting

  • +9.09%

    07 Oct 2020

+9.09%

07 Oct 2020
  • Appendix 4G and Corporate Governance Statement

    Periodic Reports

  • -3.03%

    14 Sep 2020

-3.03%

14 Sep 2020
  • Annual Report to shareholders

    Periodic Reports

  • -3.03%

    14 Sep 2020

-3.03%

14 Sep 2020
  • CDY Engages Advisers to Facilitate Divestment from Lyramid

    Asset Acquisition & Disposal

  • +3.13%

    10 Sep 2020

+3.13%

10 Sep 2020
  • FY20 Results Presentation

    Periodic Reports

  • -4.35%

    27 Aug 2020

-4.35%

27 Aug 2020
Market Data

Current Price

$0.1

52WK HIGH

$0.49

52WK LOW

$0.083

1YR RETURN

-51.22%

1YR RETURN VS. SECTOR

-68.82%

90 DAY RETURN

-16.67%

ASX RANK

1,627

/2,013

SECTOR RANK

39

/47

SHARES OUTSTANDING

125.25m
ASX:CDY

CELLMID LIMITED

Health Care

Cellmid Limited (CDY) is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets in novative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. They operate through two business segment Midikine and Consumer health.

Read more

Market Cap

12.52m

Price at Close

$0.1

4w avg. Volume

220.35k

4w avg. Turnover

$24.51k

ASX:CDY is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.